---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-000247"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:36:38.938794+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion reports preclinical data: SIL-204 systemic admin reduces pancreatic tumor growth ~50%

## Summary
- Extended-release SIL-204 reduced tumor growth ~50% after 30 days; ~50% of tumors showed complete necrosis in G12D xenografts.
- Subcutaneous SIL-204 inhibited tumor growth in mouse metastatic pancreatic orthotopic models.
- Single systemic dose maintained drug levels in rat plasma and tissues for over 56 days.
- SIL-204 inhibits multiple KRAS mutations: G12D, G12V, G12R, Q61H, and G13D.

## SEC filing metadata
- accession: 0001178913-25-000247
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/0001178913-25-000247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325000247/zk2532610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-000247
- JSON: https://secwatch.observer/filing/0001178913-25-000247.json
- Plain text: https://secwatch.observer/filing/0001178913-25-000247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.